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Valvular heart disease is responsible for a high rate of morbidity andmortality, especially in
the elderly population. With the emergence of new transcatheter treatment options, the
therapeutic spectrum for patients with valvular heart disease has considerably expanded
during the past years. Interventional treatment of the mitral and tricuspid valve requires
an individualized and versatile approach owing to the different etiologies of valvular
dysfunction and the complex anatomy of the atrioventricular valves. This article aims
to review recent developments, summarize the evidence, indications and limitations of
the available systems, and provide a glimpse into the future of transcatheter interventions
for the treatment of mitral and tricuspid valve disease.
Keywords: valvular heart disease, mitral interventions, tricuspid interventions, cardioband, mitraclip, pascal,
annuloplasty, edge-to-edge repair
INTRODUCTION
Valvular heart disease is a common condition that has long been underappreciated although it
has tremendous impact on mortality and morbidity. Population-based analyses have shown a
prevalence of moderate to severe mitral and tricuspid valve disease of 9.3 and 4.0% in the elderly
population, respectively (1, 2). The incremental annual costs for valvular heart disease in the US
are substantial [estimated at $23.4 billion (3)] and expected to further increase given population
growing and aging.
In the past, a high proportion of patients with severe mitral or tricuspid valve disease has been
denied treatment beyond medical therapy, mainly because of age and decreased left ventricular
function, both associated with high surgical risk (4). Over the last years, the interventional
landscape has widely expanded with new transcatheter methods emerging for both mitral and
tricuspid valve treatment. In contrast to transcatheter aortic valve implantation, the interventional
treatment of mitral and tricuspid valve disease requires a more versatile approach due to the
different etiologies of valvular dysfunction. This article aims to review the evolution of the field,
to discuss current indications and limitations and attempts to provide a glimpse to the future of
transcatheter interventions for mitral and tricuspid valve disease.
TRANSCATHETER MITRAL VALVE INTERVENTIONS
State of the Art
The treatment of the mitral valve has long been exclusively based on surgical mitral valve repair or
replacement. However, open-heart surgery has several limitations including low penetrance and
increased mortality in elderly patients and those with diminished left ventricular function (5).
To further improve patient care and expand the therapeutic options of severe mitral valve
disease, minimal-invasive percutaneous solutions have been introduced into clinical practice.
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Current transcatheter interventions are mostly derived from
surgical procedures. Based on their mode of action, they can
be classified into four groups: leaflet approximation, direct and
indirect annuloplasty, chordal, and valve replacement.
The MitraClip R© (Abbott Vascular, Chicago, US) device is the
first transcatheter technology with CE mark and FDA approval
for the treatment of both primary and secondary MR (6). Since
its first implantation in 2003, over 100,000 procedures have been
performed worldwide. Owing to its minimal-invasive approach
and limited interaction with the native anatomy, it carries a high
safety profile and enables fast patient’s recovery (7, 8).
The first randomized trial to assess the efficacy of the
MitraClip system was the EVEREST II trial. Two hundred and
seventy nine patients (27% with secondary MR) were assigned to
either transcatheter or surgical treatment. At 5 years, there was no
difference in terms of mortality between groups (20.8 vs. 26.8%;
p = 0.4). In primary MR, the primary endpoint (freedom from
death, MV surgery or reoperation, and 3+ or 4+ MR) occured
more frequently in the transcatheter group (54.5 vs. 23.8%; p <
0.001), mainly driven by a higher rate of surgery for recurrent
MR, whereas there was no significant difference in patients with
secondary MR (59.5 vs. 71.4%; p = 0.43). A landmark analysis
beyond 6 months through 5 years showed comparable long-term
durability with a rate of freedom from surgery for mitral valve
dysfunction of 77.7% with MitraClip vs. 76.2% with surgery (P=
0.77) (9).
In 2018, two randomized prospective trials comparing optimal
medical treatment (OMT) alone to MitraClip in addition to
OMT for patients with severe MR and heart failure have been
presented. Despite high procedural success in the MitraClip
group (92% with MR ≤ 2+), the French MITRA-FR study failed
to show any difference for the primary composite endpoint of all-
cause mortality and hospitalization for heart failure throughout
2 years (67.1% for OMT vs. 63.8% for MitraClip, HR 1.01)
(10). In contrast, the US-American COAPT study showed a
relative risk reduction of 47% (number needed to treat of
3.1) of the primary endpoint of rehospitalization for heart
failure, as well as 37% of the secondary composite endpoint of
rehospitalization or all-cause mortality after 2 years of follow-
up. Procedural success was high (98%), durable throughout 2
years (95%), and the procedure was safe (no peri-procedural
complications in 97% of patients) (11). Recently, the 3-year
follow up data have been presented, reinforcing the previous
results with an even larger symptomatic and survival benefit in
the interventional group as compared to the OMT arm (12).
Table 1 highlights the most important differences between the
two studies.
The reasons for the different outcomes of these at first sight
similar studies are the topic of an ongoing debate between experts
coming from the interventional and heart failure community.
When interpreting the above-mentioned results, the following
factors need to be considered:
(1) Discrepancies in the definition of MR severity according to
the European or American guidelines (14, 15),
(2) Exclusion of patients with severe left ventricular dilation as
well as end stage heart failure in COAPT,
TABLE 1 | Key differences between the MITRA-FR and COAPT study [adapted
from Praz et al. (13)].
MITRA-FR COAPT
Patients
(screened)
304 (452) 614 (1,576)
Age (years) 70 ± 10 72 ± 12
Key exclusion
criteria
NYHA class
< II
NYHA class < II Advanced heart
failure (ACC/AHA Stage D)
CABG or PCI
within 30
days
Untreated CAD requiring
revascularization or CABG/PCI
within 30 days
– Right-sided CHF with advanced
right ventricular dysfunction
– COPD with home oxygen
therapy or chronic oral steroid
use
– Severe tricuspid regurgitation
– sPAP > 70 mmHg unresponsive
to vasodilator therapy
Mean LVEF (%) 33 ± 7 31 ± 10
MR EROA (cm²) 0.31 ± 0.1 0.41 ± 0.15
LVEDVi (ml/m²) 135 ± 35 101 ± 34
Complications (%)* 14.6 8.5
Death or
hospitalization for
HF at 1 year (%)
54.6 33.9
OMT 51.3 46.5
Death or
hospitalization for
HF at 2 years (%)
63.8 45.7
OMT 67.1 67.9
CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary
artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; LVEF, left ventricular ejection fraction; EROA, effective regurgitant
orifice area; LVEDVi, indexed left ventricular end-diastolic volume; PHT, pulmonary
hypertension; PAP, pulmonary artery pressure.*According to MITRA-FR definition.
(3) Supervision of OMT implementation by a central
multidisciplinary committee in COAPT,
(4) Partly missing echocardiographic and clinical follow-up data
in MITRA-FR.
Compared to COAPT, patients inMITRA-FR had a higher rate of
peri-procedural complications (14.6 vs. 8.5%) as well as a lower
rate of sustained MR reduction (MR ≤ 2+ after 1 year in 83%
of the patients vs. 95% in COAPT). This is noteworthy, since
substudies of COAPT have shown residual MR (grade 3+/4+)
at 30-days to be a predictor of mortality at 2-years of follow-up.
While the state of knowledge from clinical trials and
experience is constantly evolving, the MitraClip device itself has
experienced only minor modifications, the most important being
the introduction of the XTR system with extended clip arms in
2018 (16).
The PASCAL transcatheter mitral valve repair system
(Edwards Lifesciences, Irvine, USA) has been developed to
overcome some of the intrinsic technical limitations of the
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FIGURE 1 | Case of leaflet approximation with PASCAL device in secondary MR. (A) Baseline color-Doppler echocardiographic assessment of MR. (B) Leaflet
clasping. (C) Schematic depiction of the PASCAL system (courtesy of Edwards Lifesciences). (D) Assessment of the final result with color Doppler echocardiography.
hitherto existing system. It has larger and longer arms, a central
spacer designed to fill the coaptation defect and decrease the
tension applied on the valve tissue, as well the capability to
grasp each leaflet separately. After a preliminary encouraging
compassionate experience in 23 patients (17), feasibility and
efficacy in reducing MR have been recently confirmed in a
multicenter prospective trial (18). Subsequently, the PASCAL
system has gained CE mark in February 2019 for the treatment
of both primary and secondary MR. Figure 1 shows an
illustrative case of severe secondary MR successfully treated with
implantation of one PASCAL implant.
Direct annuloplasty devices, anchored into the mitral valve
annulus, and indirect annuloplasty devices aim to reduce
annular dimensions and hence, increase leaflet coaptation in
secondary MR. The Carillon Mitral Contour System R© (Cardiac
Dimensions, Kirkland US) was the first indirect annuloplasty
device to receive CE mark (19). The recently published REDUCE
FMR study was a randomized sham-controlled trial including
120 patients, which showed a statistically significant reduction
in mitral regurgitant volume as well as left ventricular volumes
in the interventional group compared to OMT alone (20). Over
800 procedures have been performed so far. Other indirect
annuloplasty devices are under clinical evaluation, like the
ARTO R© device (MVRX, San Mateo US) (21) and the Mitral
Loop Cerclage Catheter System R© (Tau-PNU Medical, Seoul
KOR) (22), but have not received commercial approval yet. The
only direct annuloplasty device commercially available is the
Cardioband R© system (Edwards Lifesciences, Irvine US), with
favorable early results in a study of 60 patients (23). At 12
months, seven patients (12%) required a second intervention due
to recurrent MR and 61% had moderate or less MR (24).
Transcatheter chordal repair is an off-pump surgical
procedure through a transapical access aiming to restore
physiological leaflet movement through the implantation of
artificial ePTFE chords. The Harpoon R© (Edwards Lifesciences,
Irvine US) and the NeoChord R© (NeoChord, St. Louis Park US)
systems are based on this principle and are both commercially
available. Harpoon has received CE mark after the recent
presentation of the 1-year outcome data of the Mitral TRans-
Apical neoChordal Echo-guided Repair (TRACER) Trial.
TABLE 2 | Advantages and disadvantages of transcatheter mitral valve repair and
replacement.
Transcatheter mitral valve
repair
Transcatheter mitral valve
replacement
High procedural safety Some procedural risks
MR reduction
anatomy-dependent and not
always predictable
High efficacy in terms of MR
reduction (one system fits all
pathologies?)
Limited interaction with the
native anatomy
Risk of LVOT obstruction and
interaction with the subvalvular
apparatus
Low thrombogenicity Elevated risk of valve thrombosis
Risk of MR recurrence during
long-term (?)
Durable result (?)
Neochord has the largest experience with 1,200 patients treated
so far. Safety and feasibility as well as durability could be
demonstrated in the TACT trial and by registry data (25–27).
While transcatheter treatment options for mitral valve repair
have evolved rapidly over the last years, the field of transcatheter
mitral valve replacement (TMVR) is still in its infancy, mainly
limited by the high rate of screening failure due to unsuitable
anatomy. Advantages and disadvantages of TMVR compared to
repair techniques are summarized in Table 2. Two approaches
are currently being pursued: the off-label use of transcatheter
heart valves that have been originally designed for the aortic
position (mainly for valve-in-valve, valve-in-ring and valve-
in-MAC interventions) and the use of dedicated devices. The
recently reported early results of the global feasibility trial with
the Tendyne R© prosthesis (Abbott Structural, Santa Clara US)
represent the largest experience with TMVR in native mitral
valves. The system has obtained CE mark approval in January
2020. Despite high technical success and procedural safety, all-
cause mortality and hospitalization for heart failure at 1-year
follow-up were both substantial (26 and 31%, respectively) (28,
29). Several other devices are currently evaluated in clinical trials,
such as the Intrepid R© TMVR system (Medtronic, Minneapolis
US) for which favorable results have been reported in a
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pivotal study (30). Among the issues that still need to be
addressed, obstruction of the left ventricular outflow tract, valve
thrombogenicity and access route are probably the most salient.
Current Indications and Limitations
In the field of mitral valve disease, surgical treatment continues
to play a predominant role. Nonetheless, transcatheter treatment
is gaining increased significance for specific clinical scenarios and
poses a viable treatment option for well-selected patients.
Primary MR
Surgery represents the standard of care for primary MR owing
to excellent efficacy and long-term results of mitral valve
repair and should be preferred over replacement when valve
anatomy is suitable and perioperative risk acceptable (15, 31).
In patients with prohibitive surgical risk (generally due to
age), a transcatheter treatment should be evaluated by the
interdisciplinary Heart Team. Depending on the individual
anatomy of the valve and the subvalvular apparatus, an edge-to-
edge repair, chordal replacement or mitral valve replacement can
be considered (32).
Secondary MR
Guideline-directed medical treatment together with cardiac
resynchronization (if indicated) are the essential initial
therapeutic steps. In patients with persisting symptomatic
MR despite these measures, a corrective intervention should
be considered. Evidence supporting surgical treatment in this
setting is weak and survival benefit as well as result durability
are uncertain (33, 34). However, patients who require coronary
artery bypass grafting should undergo concomitant surgical valve
treatment of severe MR (15). The eligibility for edge-to-edge
repair, annuloplasty or valve replacement has to be assessed
individually using multimodality imaging. The combination
of different devices, e.g. different edge-to-edge systems or
edge-to-edge and annuloplasty, may offer an even more
individualized approach.
Bridge to Circulatory Support or Heart
Transplantation
Patients with advanced heart failure should be first evaluated for
circulatory support and heart transplantation. As an adjunctive
option, edge-to-edge reconstruction of the mitral valve may
stabilize the disease and hence, delay the need for a left-
ventricular assist device. In COAPT, progression of disease in
terms of further decrease in left ventricular function and increase
in LV dilation could be contained using the MitraClip (35) and
the number of implanted assist-devices and heart transplants was
significantly lower in the interventional group (4.4 vs. 9.5%, P =
0.01) (11).
Acute Severe Mitral Regurgitation
Acute mitral regurgitation usually requires prompt surgical
treatment while time to surgery can be bridged by stabilization
with an intra-aortic balloon pump (IABP) or Impella in addition
to medical therapy (36). Several case reports and registry data
have reported emergent edge-to-edge reconstruction to be a
feasible alternative in selected patients (37–40).
Rheumatic Mitral Stenosis
Given favorable valve morphology, percutaneous balloon
valvuloplasty remains the treatment of choice in symptomatic
patients (15). In heavily calcified anatomies, concomitant mitral
regurgitation or severe subvalvular disease, surgical intervention
is generally the only option.
Valve-in-Valve, Valve-in Ring and Valve-in-MAC
Valve-in-valve treatment of degenerated bioprostheses in the
mitral position is an option, especially in older patients with
prohibitive risk for a redo surgical procedure. A recently
published multicenter registry has shown excellent results for
ViV procedures, whereas Valve-in-ring and TMVR in heavy
calcified mitral valves (MAC) were associated with rather high
rates of procedural complications and mortality (41). The use
of a dedicated prosthesis in patients with MAC may lead to
better clinical outcomes as demonstrated by the recent experience
with the Tendyne valve (42). For mitral valve replacement
strategies, an important limitation is the potential obstruction
of the left ventricular outflow tract (LVOT) that needs to be
evaluated carefully by pre-procedural imaging like 4D computed
tomography and 3D-reconstruction, as well as 3D-printing for
implantation simulation (43–45). Intentional laceration of the
anterior mitral valve leaflet (LAMPOON) or preemptive alcohol
septal ablation have been introduced as techniques to prevent
outflow obstruction (46, 47).
What the Future Holds
Further research is needed to broaden the evidence of
transcatheter devices, observe long-term clinical outcomes and
durability, and evaluate procedural success in larger patient
cohorts. Several ongoing studies aim to show the benefit of
transcatheter treatment compared to medical therapy, surgical
treatment, or in head-to-head comparison of different devices.
The CLASP IID/F study, for example, evaluates the safety and
efficacy of the PASCAL system compared to the MitraClip
system in a non-inferiority design. Other transcatheter devices
are currently awaiting commercial approval by the FDA
and/or CE mark, like the Millipede IRIS R© (Millipede, Boston
Scientific, Marlborough US) for direct annuloplasty (48). New
iterations of the MitraClip system will provide wider clip
arms, direct measurement of left atrial pressure, as well as
optional independent leaflet grasping. The RESHAPE-HF2
trial (RandomizEd Study of tHe MitrACliP DEvice in Heart
Failure Patients With Clinically Significant Functional Mitral
Regurgitation) aims to provide further evidence for the use
of the MitraClip System in chronic heart failure patients (49),
whereas the MATTERHORN trial (Mitral vAlve reconsTrucTion
for advancEd Insufficiency of Functional or iscHemic ORigiN) is
comparing MitraClip to reconstructive mitral valve surgery (50).
Research seeking better understanding of the pathophysiology
and natural history of disease progression will enable better
patient selection and targeted, individualized device therapy.
Incipiently, many devices have been developed for the
transapical access, but especially in patients with secondary
MR and preexisting LV dysfunction, this approach has been
associated with high mortality. Currently, existing systems
Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 May 2020 | Volume 7 | Article 61
Winkel et al. Mitral and Tricuspid Interventions—Present and Future
are modified and miniaturized to be introduced via the
transfemoral/-septal access, thereby reducing the invasiveness
of the procedure and decreasing peri-procedural complications.
Compared to mitral valve repair, valve replacement has the
advantage that, especially in patients with a complex anatomy,
a nearly complete resolution of MR can be achieved. In
addition, the subvalvular apparatus remains intact. The future
of transcatheter mitral valve interventions might therefore be a
transseptal valve replacement in the vast majority of patients,
but several technical challenges have to be overcome and open
questions, like the optimal patient selection and appropriate
antithrombotic management, need to be addressed upfront.
TRICUSPID VALVE INTERVENTIONS
State of the Art
Severe tricuspid regurgitation (TR) has been neglected in the
past, as it is mainly associated with left-sided heart problems,
but also often underestimated due to challenging imaging and
grading. Meanwhile, several studies have shown TR to be an
independent prognostic predictor of worse clinical outcome and
poor survival (2, 51, 52). However, due to age, co-morbidities
and generally advanced stage of the disease, surgical treatment
is often no longer a reasonable option at the time of clinical
presentation. Nevertheless, the case volume of tricuspid valve
repair and replacement both have increased over the last years,
but in-hospital mortality after tricuspid valve surgery remains
stable (8.8%) (53, 54). In addition, surgery is associated with a
longer hospital stay and substantial costs.
Subsequently, new transcatheter treatment options have
emerged. Since most procedures were adapted from left
atrioventricular valve interventions, they follow similar
underlying principles: edge-to-edge repair enhancing leaflet
coaptation, annuloplasty aiming for annular size reduction and
valve replacement.
The most widely used transcatheter technique so far
is the MitraClip system with encouraging results (55–58):
reverse remodeling of the right ventricle (59) and improved
cardiac output (60). In patients with previously elevated liver
enzymes due to congestion a significant reduction could be
demonstrated (61).
The Cardioband direct annuloplasty system (Edwards
Lifesciences, Irvine US) has recently obtained CE approval
for the treatment of functional TR, based on the results of a
prospective observational study, which showed high technical
success (100%) and significant improvement of functional status
(88% of patients in NYHA class I-II after 6 months) (62).
Other transcatheter approaches, such as direct annuloplasty
using a caval anchoring stent, the TriCinch system, 4TECH,
Galway IRL (63) or the implantation of bicaval stenting devices
[e.g., TRICENTO,NVT,HechingenDE (64)], are currently under
clinical investigation.
Transcatheter tricuspid valve replacement (65) is a
promising alternative. However, complete resolution
of TR may be critical in patients with advanced RV
dysfunction due to potential RV failure especially
in patients with previously described pulmonary
hypertension (66).
The hitherto evidence is largely derived from registry data
and case reports. The TriValve Registry is the first large scale
international database collecting data on transcatheter tricuspid
valve interventions. The mid-term results reported a procedural
success rate of 72.8% with no difference among the different
devices (66% MitraClip, 9% CAVI, 8% FORMA, 6% Trialign,
4% Cardioband, 4% TriCinch, 3% others). Procedural failure
(residual TR ≥ grade 2+ was identified as a predictor of adverse
outcomes. Peri-procedural mortality was 0% and MACCE
occurred in 10.3% at 30-days follow-up (67).
A recently published propensity matched case-control study
comparing transcatheter valve therapy to medical treatment
alone further support the current development. In the 268
patients from the TriValve registry that were matched to solely
medically managed patients, TTVI was associated with a survival
benefit (mortality 23 ± 3% vs. 36 ± 3%, p = 0.001), as well as a
reduction of rehospitalization for heart failure (26± 3% vs. 47±
3% p < 0.0001) at 1-year follow-up (68).
Current Indications And Limitations
Transcatheter tricuspid valve interventions (TTVI) pose a
number of anatomical and technical challenges. Thinner leaflets
and larger coaptation gaps render leaflet approximation more
difficult than on the left side. Routine use of the PASCAL and
the new iteration of the MitraClip XTR system, both featuring
extended arms, may facilitate grasping (69).
The choice of the right treatment option for patients with
severe TR remains the main challenge. Figure 2 attempts
to propose a possible decision algorithm based on clinical
experience and the data available so far. Importantly, patients
with TR induced by a cardiac implantable electronic device lead
may also benefit from transcatheter treatment and the same
decision criteria apply. To determine eligibility for annuloplasty,
caval stent/valve implantation and valve replacement, advanced
imaging including multidetector computed tomography and
3D TEE are necessary. In case of advanced disease, combined
procedures may be evaluated (e.g., sequential annuloplasty and
edge-to-edge repair).
Recent data (70) also suggest the importance of a global
approach to combined mitral and tricuspid valve disease as
illustrated in Figure 3.
What the Future Holds
Patients with severe TR represent a complex and heterogeneous
population, and identifying the optimal method and timing
of treatment are crucial. Strategies adapted to the individual
stage of the disease are necessary. Further research is needed to
better understand the incidence, pathophysiology and underlying
mechanisms governing disease progression. Development of new
and validation of established imaging techniques are required for
more accurate and reproducible grading of TR severity, as well as
anatomical screening.
Dedicated prospective randomized trials are necessary to
determine the true clinical benefit of TR correction.
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FIGURE 2 | Decision algorithm for transcatheter tricuspid valve interventions. TR, tricuspid regurgitation; OMT, optimal medical therapy; PHT, pulmonary
hypertension; RV, right ventricle.
FIGURE 3 | Case of combined mitral and tricuspid edge-to-edge repair in a 79-year old sympatomatic (NYHA III) male patient with prohibitive surgical risk (Euroscore
II 21%). Baseline transesophageal assessment showed severe MR (A). After transseptal puncture, the mitral valve was treated first with the placement of one MitraClip
XTR. with MR reduction to grade 1+ (B). Severe TR at baseline (C) Two MitraClip XTR were placed in the anteroseptal commissure with reduction of TR to mild (D).
Final fluoroscopic result ((E), *MitraClip mitral, + MitraClips tricuspid).
SUMMARY
Over the last years, numerous transcatheter techniques for
the treatment of mitral and tricuspid valve disease have been
introduced. Patient volume will substantially increase over the
next years and clinical indications further expand. In contrast to
transcatheter aortic valve implantation, percutaneous treatment
of the mitral and tricuspid valves will to a lesser extent represent
an alternative to surgery, but rather address the needs of a large
population of patients that has been undertreated so far.
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